{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091691","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2026-08-06T12:30:36+00:00","discovered_at":"2026-08-06T12:35:01.361498+00:00","generated_at":"2026-08-06T12:35:26.805832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ocugen Q2 net loss $0.07/sh; closes $130M notes; OCU410 Phase 3 cleared by FDA","bullets":["Net loss $24.9M ($0.07/sh) vs $14.7M ($0.05/sh) in Q2 2025; operating expenses $17.9M.","Cash $100.4M as of June 30, 2026; closed $130M 6.75% convertible notes due 2034, net $112.5M.","FDA clearance to initiate OCU410 Phase 3 for geographic atrophy; RMAT designation granted.","Signed binding term sheet with Roots Pharmaceutical for OCU400 license in MENA: up to $255M milestones + 22% royalty.","OCU400 RP Phase 3 enrollment complete (N=140); topline Q1 2027. OCU410ST Stargardt enrollment complete (63 subjects); topline Q2 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091691","json":"https://secwatch.observer/filing/0001104659-26-091691.json","markdown":"https://secwatch.observer/filing/0001104659-26-091691.md","text":"https://secwatch.observer/filing/0001104659-26-091691.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/0001104659-26-091691-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000110465926091691/tm2622368d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:35:26.805832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}